Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

181. MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy

MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy Mucositis Guidelines MASCC Membership MASCC Meetings Practice Resources Publications Study Groups News ISOO Help MASCC Membership MASCC Meetings Practice Resources Publications Study Groups News ISOO Help MASCC/ISOO Mucositis Clinical Practice Guidelines ©MASCC, Multinational Association for Supportive Care in Cancer™ • All rights reserved worldwide. 2019 Guidelines Update - July 2019 MASCC (...) is pleased to announce the latest update of the MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy . MASCC’s Mucositis Study Group published an editorial and seven articles in a Special Section of Supportive Care in Cancer in July, 2019. The papers are available via open access until August 8, 2020. (Please log in below for links to the papers.) This is the first set of papers generated as part of this guideline update, and it represents several types

2019 International Society for Oral Oncology

182. Colorectal Cancer Screening Evidence Brief

Colorectal Cancer Screening Evidence Brief 1 Age to Initiate Colorectal Cancer Screening in Average Risk Individuals: Evidence Brief, June 2019 Key Points • Colorectal cancer incidence and mortality are increasing in individuals under age 50. • Simulation models suggest there may be benefit to screening average risk patients beginning at age 45, but it is unclear if this benefit outweighs the risks of screening • Patients age 45-49 who express interest in screening should be engaged in shared (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for colon cancer • Extra vigilance for symptoms and risk factors of colon cancer (including family history in people aged 45-49) is advised given increasing colorectal cancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectal cancer. Patients not considered average risk include those

2019 Institute for Clinical Systems Improvement

183. Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

Abemaciclib (Verzenio) - treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original

2019 Health Canada - Drug and Health Product Register

184. Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive

Entrectinib (Rozlytrek) - metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive Drug Approval Package: ROZLYTREK U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ROZLYTREK Company: Genentech Application Number: 212725, 212726 Approval Date: 08/15/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review

2019 FDA - Drug Approval Package

185. Thyroid Cancer

Thyroid Cancer Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † S. Filetti 1 , C. Durante 1 , D. Hartl 2 , S. Leboulleux 3 , L.D. Locati 4 , K. Newbold 5 , M.G. Papotti 6 , A. Berruti 7 , on behalf of the ESMO Guidelines Committee* 1 Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy; 2 Department of Head and Neck Oncology, Gustave Roussy and Université Paris Saclay, Villejuif; 3 Department of Nuclear (...) : clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: February 2008, last update September 2019. This publication supersedes the previously published version—Ann Oncol 2012; 23 (Suppl. 7): vii110–vii119. Running header: ESMO Clinical Practice Guidelines thyroid cancer Word count: 11 701 (excluding key message, references, tables & figures) Key words: papillary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, medullary thyroid cancer, management Key message (online only): ©

2019 European Society for Medical Oncology

186. New eUpdate featuring treatment algorithm for Early Colon Cancer

New eUpdate featuring treatment algorithm for Early Colon Cancer eUpdate - Early Colon Cancer Treatment Recommendations Algorithm | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO (...) with news about ESMO guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other

2019 European Society for Medical Oncology

187. Metastatic Non-Small-Cell Lung Cancer

Metastatic Non-Small-Cell Lung Cancer Updated version published 18 September 2019 by the ESMO Guidelines Committee © European Society for Medical Oncology 2019. All rights reserved. 1 CLINICAL PRACTICE GUIDELINES Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Originally published in 2018 – Ann Oncol (2018) 29 (suppl 4): iv192–iv237 D. Planchard 1 , S. Popat 2 , K. Kerr 3 , S. Novello 4 , E. F. Smit 5 , C. Faivre-Finn 6 , T. S (...) . Mok 7 , M. Reck 8 , P. E. Van Schil 9 , M. D. Hellmann 10 & S. Peters 11 , on behalf of the ESMO Guidelines Committee* 1 Department of Medical Oncology, Thoracic Group, Gustave-Roussy Villejuif, France; 2 Royal Marsden Hospital, London; 3 Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, UK; 4 Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy; 5 Thoracic Oncology Service, Netherlands Cancer Institute, Amsterdam, The Netherlands; 6 Division

2019 European Society for Medical Oncology

188. The association between cancer outcomes and time intervals to diagnosis and treatment

The association between cancer outcomes and time intervals to diagnosis and treatment SHTG Evidence Synthesis | 1 Evidence Synthesis Number 05 October 2019 In response to an enquiry from the Scottish Government Cancer Waiting Times Review Implementation Group The association between cancer outcomes and time intervals to diagnosis and treatment What were we asked to look at? To inform an ongoing clinical review of cancer waiting times in Scotland we were asked to summarise the published evidence (...) on the association between time intervals to diagnosis and treatment and cancer outcomes. Why is this important? It is important to understand the likely impact of variations in cancer waiting times across various cancer types to help ensure optimal outcomes for patients and inform planning and policy for cancer services in Scotland. What was our approach? This Evidence Synthesis provides an update to a comprehensive 2015 systematic review of time to diagnosis and treatment and its effects on cancer outcomes

2019 SHTG Advice Statements

189. Triptorelin acetate (Decapeptyl) - breast cancer

Triptorelin acetate (Decapeptyl) - breast cancer 1 Published 7 October 2019 1 SMC2186 triptorelin sustained-release 3mg powder for suspension for injection (Decapeptyl SR®) Ipsen Ltd. 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission triptorelin (Decapeptyl SR ® (...) ) is accepted for use within NHSScotland. Indication under review: As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. In premenopausal women with early breast cancer at high risk of recurrence, ovarian suppression (provided by triptorelin, oophorectomy or radiation ablation) plus an aromatase inhibitor increased disease free

2019 Scottish Medicines Consortium

190. Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC)

Enzalutamide (Xtandi) - castration-resistant prostate cancer (CRPC) 1 Published 07 October 2019 1 SMC2195 enzalutamide 40mg soft capsules (Xtandi®) Astellas Pharma Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent process (...) enzalutamide (Xtandi ® ) is not recommended for use within NHSScotland. Indication under review: The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC). In a phase III study in men with high-risk non-metastatic CRPC enzalutamide was superior to placebo for metastasis-free survival. High-risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2 nanograms/mL. Both groups received on-going androgen-deprivation therapy or had undergone

2019 Scottish Medicines Consortium

191. Pertuzumab (Perjeta) - HER2-positive early breast cancer

Pertuzumab (Perjeta) - HER2-positive early breast cancer 1 Published 07 October 2019 1 SMC2197 pertuzumab 420mg concentrate solution for infusion (Perjeta®) Roche Products Ltd 06 September 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission considered under the orphan equivalent (...) process pertuzumab (Perjeta®) is not recommended for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence. The addition of pertuzumab to trastuzumab and chemotherapy improved invasive disease- free survival in patients with HER2-positive early breast cancer at high risk of recurrence. Overall survival data are immature. The submitting

2019 Scottish Medicines Consortium

192. Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary

Assessment and management of bone health in women with oestrogen receptor?positive breast cancer receiving endocrine therapy: position statement summary Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page (...) doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Assessment and management of bone health in women with oestrogen receptor‐positive breast cancer receiving endocrine therapy: position statement summary Mathis Grossmann, Sabashini K Ramchand, Frances Milat, Amanda Vincent, Elgene Lim, Mark A Kotowicz, Jill Hicks and Helena J Teede Med J Aust 2019; 211 (5

2019 MJA Clinical Guidelines

193. The Impact of Adverse Childhood Experiences on the Utilization of Cervical Cancer Screening

The Impact of Adverse Childhood Experiences on the Utilization of Cervical Cancer Screening "The Impact of Adverse Childhood Experiences on the Utilization of Cerv" by Jennifer Mings < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Abstract Background: Adverse childhood experiences (ACEs) are prevalent for many women, and have been proven to lead to an increase in chronic (...) diseases including cancer. While the mechanism behind this is not completely understood, the literature suggests that it may be partially due to decreased utilization of cancer screening. Due to the widespread nature of cervical cancer, this literature review seeks to investigate the relationship between ACEs and cervical cancer screening. Methods: An exhaustive literature search of MEDLINE-PubMed, Web of Science, Public Health Database, and PyschINFO was performed. The keywords used in the search

2019 Pacific University EBM Capstone Project

194. The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence

The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence "The Effects of a Plant-Based Diet and Stress Reduction Techniques on P" by Amanda Barclay and Jacob McAvoy < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Prostate cancer is the most common cancer affecting men. It is also very common for men (...) to suffer from recurrence after primary therapy is completed. The current most commonly used therapies for prostate cancer recurrence, hormonal therapy and radiation, have significant side effects. It is known that diet influences cancer prevention, progression, and recurrence. A plant-based diet, especially when combined with stress reduction techniques, may be a useful therapeutic option with fewer side effects for men with recurrent prostate cancer. This review examines the effects of a plant-based

2019 Pacific University EBM Capstone Project

195. Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT

Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} There is insufficient evidence to conclude that robotic rectal cancer surgery compared with laparoscopic surgery reduces the risk of conversion to laparotomy, and overall it results in comparable outcomes and it was more expensive. {{author}} {{($index , , , , , , , , , & . David Jayne 1, * , Alessio Pigazzi 2 , Helen Marshall 3 , Julie Croft 3 , Neil Corrigan 3 , Joanne Copeland 3 , Philip Quirke 4 , Nicholas

2019 NIHR HTA programme

196. Updated treatment recommendations for Early Colon Cancer

Updated treatment recommendations for Early Colon Cancer Early Colon Cancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates.​ Connect with ESMO Discover ESMO's new social (...) guidelines, including the latest CPG publications, updated recommendations, algorithms, pocket guidelines and MCBS grading ESMO Guidelines Slide Sets Quick and easy access to the essential content of the guidelines – PowerPoint slides and PDFs including algorithms, figures and tables – free to download Breast Cancer Early Breast Cancer • 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC4) • Prevention and Screening in BRCA Mutation Carriers and Other Breast/Ovarian

2019 European Society for Medical Oncology

197. Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material (...) Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women Variant 1: Newly diagnosed. Initial workup. Rule out bone metastases. Radiologic Procedure Rating Comments RRL* FDG-PET/CT whole body 2 ???? Tc-99m bone scan whole body 1 ??? X-ray skeletal survey 1 ??? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually

2019 American College of Radiology

198. Post-Treatment Surveillance of Bladder Cancer.

Post-Treatment Surveillance of Bladder Cancer. Date of origin: 1996 Last review date: 2014 ACR Appropriateness Criteria ® 1 Surveillance Imaging of Bladder Cancer American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Post-Treatment Surveillance of Bladder Cancer Variant 1: Superficial TCC; no invasion or risk factors. Radiologic Procedure Rating Comments RRL* CT abdomen and pelvis without and with IV contrast 3 Consider this procedure if metastatic disease (...) with IV contrast 1 ??? CT chest without IV contrast 1 ??? CT chest without and with IV contrast 1 ??? CT abdomen and pelvis with IV contrast 1 ???? CT abdomen and pelvis without IV contrast 1 ???? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Post-Treatment Surveillance of Bladder Cancer Clinical Condition: Post-Treatment Surveillance of Bladder Cancer Variant 2: Superficial TCC; no invasion

2019 American College of Radiology

199. Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer.

Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. American College of Radiology End User License Agreement ACR Appropriateness Criteria is a registered trademark of the American College of Radiology. By accessing the ACR Appropriateness Criteria®, you expressly agree and consent to the terms and conditions as described at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/TermsandConditions.pdf Personal use of material is permitted for research (...) abdomen and pelvis without and with IV contrast 8 This procedure is equivalent to CT. O CT abdomen and pelvis without and with IV contrast 6 This procedure is particularly appropriate if the patient is postablation or has a hereditary renal cancer syndrome. The noncontrast scan is not needed in the pelvis. ???? CT chest with IV contrast 6 This procedure is particularly appropriate if patients are considered at high risk for metastatic disease. ??? CT chest without IV contrast 5 This procedure

2019 American College of Radiology

200. HPV Testing for Primary Cervical Cancer Screening

HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening | CADTH.ca Find the information you need HPV Testing for Primary Cervical Cancer Screening HPV Testing for Primary Cervical Cancer Screening Published on: March 26, 2019 Project Number: OP0530-000 Product Line: Result type: Report Worldwide, cervical cancer is one of the most frequently diagnosed cancers; however, the incidence of cervical cancer has been decreasing in the past three decades (...) , largely due to routine screening with cytology. HPV is the major risk factor for the development of cervical cancer, with 99% of cervical cancer being associated with HPV. It is one of the most common sexually transmitted infections in the world and about three out of every four sexually active Canadians will have at least one HPV infection at some point in their lives. In view of the anticipated higher sensitivity of HPV testing, some experts and stakeholders have called for HPV testing to be used

2019 CADTH - Optimal Use